Therefore, targeting PARP1 in a setting of high genomic instability, as seen in DLBCL, and high NF-kB activation, as seen in the ABC type DLBCL [49], is an understandable choice. This evidence concerns the gene NFKB1 and diffuse large B-cell lymphoma.